Taro Pharmaceutical Industries (TARO) gains 2.13% for July 21

Equities Staff  |

Taro Pharmaceutical Industries (NYSE: TARO) shares gained 2.13%, or $1.47 per share, to close Wednesday at $70.57. After opening the day at $69.64, shares of Taro Pharmaceutical Industries fluctuated between $71.44 and $69.48. 22,800 shares traded hands an increase from their 30 day average of 21,868. Wednesday's activity brought Taro Pharmaceutical Industries’s market cap to $2,676,440,925.

Taro Pharmaceutical Industries is headquartered in 14 Hakitor Street Po Box 10347, Haifa..

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.

Visit Taro Pharmaceutical Industries’s profile for more information.

About The New York Stock Exchange

The New York Stock Exchange is the world’s largest stock exchange by market value at over $26 trillion. It is also the leader for initial public offerings, with $82 billion raised in 2020, including six of the seven largest technology deals. 63% of SPAC proceeds in 2020 were raised on the NYSE, including the six largest transactions.

To get more information on Taro Pharmaceutical Industries and to follow the company’s latest updates, you can visit the company’s profile page here: Taro Pharmaceutical Industries’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content